Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression in newly diagnosed diabetes subclinical vascular lesions

AIM:To investigate the effect of Danzhijiangtang capsule(DJC) on monocyte chemoattractant protein-1(MCP-1) mRNA expression in newly diagnosed type 2 diabetes mellitus(T2DM) subclinical vascular lesions.METHODS:Sixty-two patients with newly diagnosed T2DM subclinical vascular lesions were randomly divided into a control group and treatment group of 31 cases each.Oral antidiabetic therapy with routine western medicine was conducted in both groups,and the treatment group was additionally treated with DJCs.The treatment course for both groups was 12 wk.Before and after treatment,the total efficiency and traditional Chinese medicine(TCM) syndrome score were calculated.The fasting plasma glucose(FPG),2-h plasma glucose(2hPG),fasting insulin(FINS),insulin resistance index(IRI),hemoglobin(Hb)A1c,blood lipids,and hemorheology indices were determined.In addition,the levels of vascular endothelial growth factors including thrombomodulin(TM),von Willebrand factor(vWF),P-selectin and MCP-1 mRNA were determined.RESULTS:After 12 wk of treatment,the TCM syndrome score was significantly decreased compared to before treatment in both groups.After treatment,FPG,2hPG,HbA1c,FINS,IRI,total cholesterol,triglycerides,low-density lipoprotein,high-density lipoprotein,whole blood low shear specific viscosity,plasma specific viscosity,TM,vWF,P-selectin and MCP-1 mRNA were significantly improved compared to before treatment in both groups.After treatment,the total efficiency and TCM syndrome score in the treatment group were better than in the control group.FINS,IRI,whole blood high shear specific viscosity,plasma specific viscosity,TM,vWF,P-selectin and MCP-1 mRNA level in the treatment group were significantly reduced after treatment compared with control group.CONCLUSION:DJCs are efficacious in supplementing qi,nourishing yin and invigorating blood circulation,and upregulate MCP-1 mRNA expression in patients with T2DM subclinical vascular lesions.

Effects of Simvastatin on NF-κB-DNA Binding Activity and Monocyte Chemoattractant Protein-1 Expression in a Rabbit Model of Atherosclerosis

To observe the effects of simvastatin on nuclear factor kappaB （NF-kB）-DNA binding activity and on the expression of monocyte chemoattractant protein-1 （MCP-1） in atherosclerotic plaque in rabbits and to explore the anti-atherosclerotic properties beyond its lipid-lowering effects. Thirty-six New Zealand male rabbits were randomly divided into low-cholesterol group （LC）, high- cholesterol group （HC）, high-cholesterol＋ simvastatin group （HC＋S） and then were fed for 12 weeks. At the end of the experiment, standard enzymatic assays, electrophoretic mobility shift as- say （EMSA）, immunohistochemical staining, and morphometry were performed to observe serum lipids, NF-kB-DNA binding activity, MCP-1 protein expression, intirna thickness and plaque area of aorta respectively in all three groups. Our results showed that the serum lipids, NF-kB-DNA binding activity, expression of MCP-1 protein, intima thickness, and plaque area of aorta in the LC and HC＋S groups were significantly lower than those in the HC group （P〈0.05）. There was no significant difference in the serum lipids between the LC and HC＋S groups （P〉0.05）, but the NF-kB-DNA binding activity, the expression of MCP-1 protein and the intirna thickness and plaque area of aorta in the HC＋S group were significantly decreased as compared to the LC group （P〈0. 05）. This study demonstrated that simvastatin could decrease atherosclerosis by inhibiting the NF-kB-DNA binding activity and by reducing the expression of MCP-1 protein.

Expression of Monocyte Chemoattractant Protein-1 in Monocytes and Effects of Native and Oxidized Very Low Density Lipoproteins

Monocyte chemoattractant protein-1(MCP-1), a potent chemoattractant, is thought to play an important role in migration of monocytes into atherosclerotic lesions. The present study was designed to investigate the capacity of human peripheral blood monocytes to express MCP-1 and effects of native very low density lipoprotein (VLDL) and oxidized VLDL(OX-VLDL) on the expression. The total RNA was extracted from cultured monocytes, which were exposed to VLDL and OX-VLDL, and the media conditioned by monocytes were collected. MCP-1 mRNA expression was examined by Northern blot analysis. MCP-1 protein in conditioned media was determined by using sandwich ELISA. The results showed that monocytes can express MCP-1 after a 24 h incubation at 37℃，and the expression was markedly increased by a exposure to OX-VLDL, whereas the expression was slightly increased when exposed to VLDL. It suggests that the capacity of monocytes to produce MCP-1 that recruits and activates circulating monocytes may be of considerable importance in atherogenesis, and oxidation of VLDL enhances its potential to promote atherogenesis.

Correlation of serum cyclophilin A and monocyte chemoattractant protein-1 levels with carotid atherosclerosis in patients with acute cerebral infarction

Objective:To study the correlation of serum cyclophilin A (CyPA) and monocyte chemoattractant protein-1 (MCP-1) levels with carotid atherosclerosis in patients with acute cerebral infarction.Methods: 106 patients with acute cerebral infarction who were hospitalized in our hospital between July 2011 and August 2015 were selected as observation group, and 50 cases of healthy persons who received physical examination in our hospital during the same period were selected as normal control group. The serum CyPA and MCP-1 contnets in two groups were determined. According to the median of CyPA and MCP-1 contents in observation group, they were divided into high CyPA group and low CyPA group as well as high MCP-1 group and low MCP-1 group, 53 cases in each group. Contents of lipid metabolism indexes and carotid atherosclerosis illness-related indicators were compared between acute cerebral infarction patients with different CyPA and MCP-1 contents.Results:Serum CyPA and MCP-1 contents in observation group were significantly higher than those in control group. Serum TC, LP(a) and LDL-C contents in high CyPA group and high MCP-1 group were higher than those in low CyPA group and low MCP-1 group while HDL-C contents were lower than those in low CyPA group and low MCP-1 group. Serum CysC, Hcy and UA contents in high CyPA group and high MCP-1 group were higher than those in low CyPA group and low MCP-1 group.Conclusion: Serum CyPA and MCP-1 contents in patients with acute cerebral infarction are higher than those in normal population, and the contents of CyPA and MCP-1 are positively correlated with the degree of carotid atherosclerosis.

The enhancement of astrocytic-derived monocyte chemoattractant protein-1 induced by the interaction of opiate and HIV tat in HIV-associated dementia

HIV-associated dementia(HAD)is a public health problem and is particularly prevalent in drug abusers.The neuropathogenesis of human immunodeficiency virus(HIV)infection involves a complex cascade of inflammatory events,including monocyte/macrophage infiltration in the brain,glial immune activation and release of neurotoxic substances.In these events,astrocytic-derived monocyte chemoattractant protein-1(MCP-1)plays an important role,whose release is elevated by HIV transactivator of transcription(HIV tat)and could be further elevated by opiates.This review will also consider some critical factors and events in MCP-1 enhancement induced by the interactions of opiate and HIV tat,including the mediating role of mu opioid receptor(MOR)and CCR2 as well as the possible signal transduction pathways within the cells.Finally,it will make some future perspectives on the exact pathways,new receptors and target cells,and the vulnerability to neurodegeneration with HIV and opiates.

Variation of Serum Monocyte Chemoattractant Protein-1 in Patients with Diabetes and Metabolic Syndrome

This study investigated the variation of serum monocyte chemoattractant protein-1（MCP-1） in patients with both diabetes mellitus（DM） and metabolic syndrome（MS）.Based on the International Diabetes Federation（IDF） diagnostic criteria,93 patients enrolled in this study were divided into four groups：normal control（NC）,simple DM,simple MS,and DM plus MS（DM-MS） groups.The main measures included height,weight,waist circumference（WC）,hip circumference,blood pressure,fasting blood glucose,insulin resistance index（HOMA-IR）,serum triglyceride（TG）,HDL-ch,LDL-ch,and MCP-1.The results showed that the serum levels of MCP-1 in the DM-MS group were significantly increased as compared with those in the DM and MS groups（P0.05）,and the increase in the MCP-1 level in the DM group was much higher than in the MS group（P0.05）.The DM-MS group had the highest HOMA-IR levels,followed by MS,DM and NC groups（P0.05）.Correlation tests showed that the association of MCP-1 with age,HDL-ch,or LDL-ch was insignificant,whereas that of MCP-1 with body mass index（BMI）,waist hip rate（WHR）,WC,systolic blood pressure（SBP）,diastolic blood pressure（DBP）,TG,and HOMA-IR was significantly positive.It was concluded that circulating MCP-1 was substantially increased in patients with both DM and MS as compared with that in the patients with DM or MS alone,and the central obese state may contribute to a more vicious proinflammatory condition and insulin resistance in patients with diabetes.

Effect of monocyte chemoattractant protein-1 on chemotactic gene expression by macrophage cell line U937

Objective: To study the chemotactic superfamily genes expression profiling of macrophage line U937 treated with monocyte chemoattractant protein-1 (MCP-1) using gene chip technique. Methods: Total RNA from macrophage line U937 (as control) and U937 with MCP-1 was extracted, made reverse transcript to cDNA and tested with gene expression chip HO2 human. Results: Some chemotactic-related gene expressions were changed in all analyzed genes. Regulated upon activation, normal T cell expressed and secreted (RANTES) was up-regulated over 2-fold and 7 chemotactic-related genes (CCR2, CCR5, CCL16, GROβ, GROγ, IL-8 and granulocyte chemotactic protein 2) were down-regulated over 2-fold in MCP-1 treated U937 cells at mRNA level. Conclusion: MCP-1 can influence some chemokines and receptors expression in macrophage in vitro, in which MCP-1 mainly down-regulates the chemotactic genes expression of those influencing neutrophilic granulocyte (GROβ, GROγ, IL-8 and granulocyte chemotactic protein 2). Another novel finding is that it can also down-regulate the mRNA level of CCR5, which plays a critical role in many disorders and illnesses.

Monocyte chemoattractant protein-1 plays a key role in type 1 diabetes

Type 1 diabetes is an autoimmune dise as e resulting from the selective destruction of β cells in the pa ncreatic islets. In both human and rodent models of type 1 diabetes, the clinica l disease is preceded by a progressive mononuclear cell invasion of the pancreat ic islets (insulitis). In the early stage of insulitis,the major components are monocyte/macrophages, and the recruitment of mononuclear cells is a critical st ep in the pathogenesis of the type 1 diabetes. Studies have revealed that Monocy te chemoattractant protein-1(MCP-1) specifically recruits monocytes/ macrophag es into pancreas and plays an important role in the development of insulitis and diabetes.

Effect of Llinagliptin on tumor necrosis factor receptor and monocyte chemoattractant protein-1 in patients with diabetic nephropathy

Objective:To explore the effect of Linagliptin on tumor necrosis factor receptor and monocyte chemoattractant protein-1 in patients with diabetic nephropathy.Methods: A total of 98 patients with diabetic nephropathy admitted to the Hospital from January 2017 to September 2018 were enrolled. The patients were divided into two groups according to the random double-blind method, with 49 cases in each group. The control group was treated with Metformin, whereas the experimental group was treated with Linagliptin plus Metformin. After 3 months of continuous treatment, the renal function [urinary albumin excretion rate, 24 h urine protein quantitation and serum creatinine], glycolipids metabolic levels [glycated hemoglobin, fasting blood glucose, total cholesterol and triglycerides], monocyte chemoattractant protein-1, tumor necrosis factor receptor, high-sensitivity C-reactive protein, and adverse reactions were compared between the two groups.Results:After 3 months of treatment, the levels of UAER, 24 h Upor and Scr in the experimental group were shown to be lower than those in the control group, and the difference was statistically significant. After 3 months of treatment, the levels of HbA1c, FPG, TC and TG in the experimental group were shown to be lower than the control group, and the difference was statistically significant. After 3 months of treatment, the levels of MCP-1, sTNFR1 and hs-CRP in the experimental group were lower than those in the control group, and the difference was statistically significant. There was no significant difference in incidence of adverse reactions between the two groups.Conclusion: For patients with diabetic nephropathy, Linagliptin is with higher safety, which can help improve their glycolipids metabolic levels and renal function, reduce the inflammatory response and the levels of MCP-1 and sTNFR1, and yet incur fewer adverse reactions.

Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C

AIM:To explain the role of Monocyte chemotactic protein-1 (MCP-1) and soluble adhesion molecules in chronic hepatitis C during the treatment of interferon alpha (IFNα) 2 b and ribavirin (RBV). METHODS:Concentrations of MCP-1,soluble adhesion molecules intercellular adhesion molecule-1 (sICAM-1),sP- selectin,interleukin (IL) 6,and IL10 in serum were estimated in the group of 40 patients with chronic hepatitis C treated with IFNalpha2 b and RBV in 0,16,32,48 wk of the therapy, RESULTS:In chronic hepatitis C,before and during the treatment,the serum levels of MCP-1 and sP-selectin in responders were similar to those of healthy subjects.In non- responders (NR),MCP-1 increased in the course of IFNc^+RBV treatment,differences were statistically significant as compared to responders.MCP-1 correlated statistically with the activity of periportal inflammation (r=0.35,P<0.05) but not with staging of liver fibrosis,sICAM-1 positively correlated with inflammatory activity and fibrosis in NR.sP-selectin did not correlate with histological findings in the liver.The MCP-1 correlated with the soluble form of sP-selectin concentrations (r= 6,P<0.001) and with IL-10 level in NR (r=0.4,P<0.05).There was no correlation observed between the concentration of MCP-1 and sICAM-1,IL-6 during the treatment. CONCLUSION:MCP-1 concentration may be a prognostic marker of the efficacy of IFN+RBV therapy in patients with chronic hepatitis C.

Efficacy of recombinant human osteoprotegerin combined with tinidazole in the treatment of periodontitis mice and its correlation with serum RANKL and MCP-1 levels

Objective: To investigate the effect of recombinant human osteoprotegerin combined with tinidazole on mice with periodontitis and the effect on serum RANKL and MCP-1 levels. Methods: 80 SPF-cleaned mice were randomly divided into 4 groups, 20 each, model group, tinidazole group and recombinant human osteoprotegerin group were modeled by Kimura et al., and tinidazole group received tinidazole. After intragastric administration, the recombinant human osteoprotegerin group was injected with recombinant human osteoprotegerin in the periodontal pocket according to the tinidazole group. The periodontal changes of the four groups of mice were observed and recorded, and the gingival rating was performed. Epithelial tissue morphology was observed by hematoxylin-eosin (HE) staining. Serum levels of IL-4, IL-6, RANKL and MCP-1 were measured by enzyme-linked immunosorbent assay. Results:After the intervention, the model group developed severe inflammatory reactions, including redness, hemorrhage, and deep periodontal pockets. The teeth were significantly loosened. The mice in the tinidazole group and the recombinant human osteoprotegerin group recovered substantially, and the gingival rating of the recombinant human osteoprotegerin group was better than that. The tinidazole group and the model group (P<0.05). The results of HE staining showed that the model group had edema, vasodilation and a large amount of inflammatory infiltration. The epithelial structure of the mice in the tinidazole group and the recombinant human osteoprotegerin group was intact and arranged closely and orderly. After intervention, the IL-4 in the tinidazole group and the recombinant human osteoprotegerin group was significantly higher than the model group and IL-6 was significantly lower than the model group (P<0.05), and the recombinant human osteoprotegerin group IL-4 was significantly higher after the intervention. IL-6 was significantly lower in the tinidazole group than in the tinidazole group (P<0.05). After the intervention, the tinidazole group and the recombinant human osteoprotegerin group were significantly reduced, and the recombinant human osteoprotegerin group RAKNL and MCP-1 were significantly lower than the model group (P>0.05). Conclusion: Recombinant human osteoprotegerin combined with tinidazole has a better therapeutic effect on gums and teeth in mice with periodontitis, and can lower the levels of RAKNL and MCP-1 in serum, inhibit bone resorption and protect teeth.

The Effects and Mechanism of GSA on Expression of MCP-1 in Cultured Human Umbilical Vein Endothelial Cells

Objectives To investigate the effects and mechanism of glycated serum albumin(GSA) on expression of Monocyte chemoattratant protein-1(MCP-1) in Endothelial Cells. Methods Human Umbilical Vein Endothelial Cells (HUVEC)are cultured with GSA of different concentrations and interfered by glycosylation products inhibitor Aminoguanidine (AG) and anti-oxidant N-acetylcy-steine (NAC), The expression of MCP-1 are evaluated by Immunocytochemistry and Sandwich ELISA. MDA content and SOD activity are determined by the technique of TBA and XOD respectively. Results GSA can stimulate MCP-1 production and secretion. Immunocytochemistry showed that after HUVECs were cultured with 50 mg/L GSA, expression of MCP-1 in group 4hrs, 8hrs and 12hrs was 1.3, 1.9 and 2.8 fold as much as that in control group (P < 0.01), and there was significant difference among the experiment groups(P < 0.01). Sandwich ELISA showed that expression of MCP-1 in three different groups was 1.6, 2.4 and 3.0 fold as much as that in control group(P < 0.01), and there was significant difference among the experiment groups(P < 0.01); GSA can cause the decrease of SOD activity(P < 0.05) and increase of MDA content(P < 0.01); AG and NAC can restrain obviously the expression of MCP-1 of HUVECs stimulated by GSA(P < 0.01); NAC can restrain the effect of GSA on SOD activity and MDA content in HUVECs (P < 0.05). Conclusions GSA can stimulate the expression of MCP-1 of endothelial cells by inducing endothelial cells oxidative stress.

神经肽P物质诱导高糖条件下人皮肤成纤维细胞分泌MCP-1的分子机制

目的探讨神经肽P物质(SP)诱导高糖培养环境中的人皮肤成纤维细胞分泌单核细胞趋化蛋白1(MCP-1)的分子机制。方法采用高糖DMEM培养基培养人皮肤成纤维细胞,加入同一浓度(10 nmol/L)SP孵育不同时间,Western blotting检测细胞中核因子κB(NF-κB)抑制蛋白α(IκBα)、磷酸化IκBα(p-IκBα)和磷酸化NF-κB亚单位p65(p-NF-κBp65)的表达,免疫荧光方法观测细胞p-NF-κBp65表达和转位情况。将高糖DMEM培养基培养人皮肤成纤维细胞分为对照组、SP组和SP+NF-κB抑制剂(MG132)组(以MG132预处理细胞60 min),Western blotting检测各组细胞内p-NF-κBp65的表达,ELISA方法测定细胞培养上清液中MCP-1的浓度。结果随着SP作用时间的延长,成纤维细胞IκBα的表达量显著减少,p-IκBα的表达量显著增加(P<0.05);同时p-NF-κBp65的表达量在SP作用后显著增加(P<0.05),并保持递增趋势;免疫荧光染色激光共聚焦显微镜观察证实SP作用后细胞胞核内p-NF-κBp65表达增强。与SP组比较,SP+MG132组细胞p-NF-κBp65表达及细胞培养上清液中MCP-1浓度均显著降低(P<0.05)。结论 SP促进人皮肤成纤维细胞分泌MCP-1的作用机制可能与NF-κB信号通路激活有关。

p38MAPK介导Ghrelin对TNF-α诱导的人脑微血管内皮细胞MCP-1 mRNA表达的抑制

目的探讨Ghrelin对TNF-α诱导的人脑微血管内皮细胞(HBMEC)单核细胞趋化蛋白1(MCP-1)的影响及p38MAPK的作用。方法培养HBMEC,TNF-α组加入不同浓度TNF-α;Ghrelin预处理组先加入Ghrelin预处理1 h后,加入TNF-α。采用RT-PCR法检测MCP-1 mRNA的水平,免疫印迹法检测磷酸化p38(p-p38)的表达。结果经TNF-α刺激后,MCP-1 mRNA表达明显增强,并呈一定的浓度剂量依赖关系(P<0.05),胞质中的p-p38蛋白表达亦明显增加(P<0.05)。Ghrelin预处理可以减少MCP-1 mRNA及胞质中的p-p38蛋白表达(P均<0.05)。结论 Ghrelin可能通过抑制p-p38通路抑制TNF-α介导的HBMEC MCP-1 mRNA表达。

MCP-1转染人脐静脉内皮细胞过表达/沉默后相关信号通路研究

目的探讨单核细胞趋化蛋白-1(MCP-1)转染人脐静脉内皮细胞过表达/沉默后相关信号通路与深静脉血栓形成的关系。方法培养人脐静脉内皮细胞行免疫荧光、免疫共沉淀检测,构建人MCP-1细胞系过表达/沉默载体,基因表达谱芯片检测人MCP-1细胞系过表达/沉默后转录谱变化并行生物信息技术分析。结果培养人脐静脉内皮细胞;构建人MCP-1过表达/干扰载体MCP-1-p CDH-GFP/MCP-1-LMP sh RNAmir1经病毒转染后感染HUVECs;基因芯片检测发现与正常细胞相比,过表达载体MCP-1-p CDH-GFP转染细胞有18条信号通路下调,7条信号通路上调;干扰载体MCP-1-LMP sh RNAmir1转染细胞有60条信号通路下调,15条信号通路上调。结论MCP-1转染人脐静脉内皮细胞后相关信号通路为深静脉血栓疾病分子层面研究提供新的思路,MCP-1可能在深静脉血栓形成发生发展过程中发挥重要作用。

α-硫辛酸对高糖诱导的人外周血单个核细胞MCP-1、ICAM-1表达的影响

目的探讨 α-硫辛酸（ALA）对体外高糖（HG）刺激的人外周血单个核细胞（PBMC）中单核细胞趋化蛋白-1（MCP-1）、细胞间黏附分子-1（ICAM-1）水平的影响。方法在体外条件下采用正常糖组（NG组）、高渗组（HS组）、HG组和HG＋不同浓度ALA组（ALA50组、ALA100组、ALA250组）与人PBMC共同培养24h和48h，并分别测定各组细胞培养上清液中MCP-1、ICAM-1蛋白的浓度。结果（1）HG组各时段的细胞培养上清液中MCP-1和ICAM-1蛋白水平均较NG组显著增高（均P〈0.01）；（2）ALA100组和ALA250组培养48h时的细胞上清液中MCP-1蛋白水平均较HG组显著降低（均P〈0.01），且两组MCP-1蛋白水平均较培养24h时降低（均P〈0.05），而ALA250组各时段的蛋白水平均较ALA100组降低（均P〈0.01）；（3）ALA100组和ALA250组各时段的细胞培养上清液中ICAM-1蛋白水平均较HG组显著降低（均P〈0.01），而两组各时段ICAM-1蛋白水平的差异则无统计学意义（均P〉005），ALA250组各时段的蛋白水平均较ALA100组降低（均P〈0.01）。结论HG可刺激人PBMC中MCP-1、tCAM-1蛋白分泌水平增高；ALA则可降低MCP-1、ICAM-1蛋白的表达，目其疗效与药物浓度和作用时间相关。

利用PCR技术优化人单核细胞趋化蛋白-1(MCP-1)基因

本研究利用ＰＣＲ技术将人单核细胞趋化蛋白－１基因（ＭＣＰ－１）５′端翻译起始区进行优化改构。结果表明，改构后的ＭＣＰ－１基因克隆入大肠杆菌表达载体ｐＢＶ２２０中，ＤＮＡ测序证实正确。上述结果为进一步研究ＭＣＰ－１的高效表达奠定了基础。

糖化白蛋白对人脐静脉内皮细胞MCP-1表达的影响及其机制研究

目的:探讨糖化白蛋白对内皮细胞中单核细胞趋化蛋白-1(MCP-1)表达的影响及其机制。方法:将人脐静脉内皮细胞(HUVECs)与不同浓度的糖化白蛋白共同培养,并用糖基化产物抑制剂氨基胍(AG)和抗氧化剂N-乙酰半胱氨酸(NAC)干预。分别用免疫细胞化学和夹心ELISA方法测定细胞MCP-1的表达,硫代巴比妥酸法和黄嘌呤氧化酶法测定细胞内丙二醛含量和超氧化物歧化酶活性。结果:糖化白蛋白促进HUVECs合成和分泌MCP-1。免疫细胞化学显示,HUVECs暴露于50mg/L糖化白蛋白后,随作用时间的延长(4 h、8 h、12h),MCP-1的表达增高(P<0.01),分别为对照组的1.3、1.9和2.8倍(P<0.01);糖化白蛋白能引起细胞内超氧化物歧化酶活性下降(P<0.05)和丙二醛含量升高(P<0.01)。氨基胍和N-乙酰半胱氨酸能抑制糖化白蛋白刺激内皮细胞表达MCP-1(P<0.01),N-乙酰半胱氨酸能抑制糖化白蛋白对内皮细胞内超氧化物歧化酶和丙二醛的影响(P<0.05)。结论:糖化白蛋白可刺激人类内皮细胞表达MCP-1,糖化白蛋白刺激MCP-1表达与其诱导细胞内氧化应激有关。